Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the
“Company”), a biotechnology company developing next-generation cell
and gene therapies using its proprietary Gene Circuit platform,
including SENTI-202, a Logic Gated off-the-shelf CAR-NK
investigational cell therapy in Phase 1 clinical trials, today
announced its participation at the following investor conferences:
- H.C. Wainwright’s 26th Annual Global Investment
ConferenceFormat: Presentation and 1x1 MeetingsLocation:
New York, NYPlease click here to access the pre-recorded
presentation (available September 9, 2024, at 7:00 a.m. ET)
- Chardan's 8th Annual Genetic Medicines
ConferenceFormat: Fireside Chat and 1x1 MeetingsDate:
September 30, 2024, at 5:00 p.m. ETLocation: New York, NYPlease
click here to access the live webcast
Archived replays can be accessed through the Events &
Presentations section of the Senti Bio website and will be
available for approximately 90 days following each event. For
additional information or to schedule a one-on-one meeting, please
email investors@sentbio.com.
About SENTI-202SENTI-202 is a Logic Gated
off-the-shelf chimeric antigen receptor natural killer (“CAR-NK”)
cell therapy product candidate designed to selectively target and
eliminate CD33 and/or FLT3 expressing hematologic malignancies,
such as AML and myelodysplastic syndrome (“MDS”), while sparing
healthy bone marrow cells. SENTI-202 has three main components.
First, the OR GATE, which is an activating CAR that targets CD33
and FLT3. By targeting either or both of these antigens, SENTI-202
could effectively kill both the leukemic blasts and leukemic stem
cells that form an important basis for AML disease. Second, the NOT
GATE, which is designed to recognize the healthy cells and protect
those healthy cells from being killed. Third, the
calibrated-release IL-15 technology, which is designed to
significantly increase cell persistence, expansion and activity of
both the CAR- NK cells and the host immune cells. The NK cells used
to construct SENTI-202 are sourced from healthy adult donors, which
have been screened based on a set of criteria that reflect
manufacturability and product quality, and are then cryopreserved
prior to use in manufacturing to minimize variability. Senti Bio is
currently enrolling adult patients with r/r CD33 and/or FLT3
expressing hematologic malignancies in a Phase 1 clinical trial for
SENTI-202, which can be a potential first-in-class allogeneic
treatment for AML/MDS patients. Senti Bio anticipates releasing
initial clinical trial results for SENTI-202 by year-end 2024.
Senti Bio has published SENTI-202 preclinical data demonstrating
the potential of Logic Gated CAR-NK cell therapy for the treatment
of AML.
About Senti BioSenti Bio is a biotechnology
company developing a new generation of cell and gene therapies for
patients living with incurable diseases. To achieve this, Senti Bio
is leveraging a synthetic biology platform called Gene Circuits to
create therapies with enhanced precision and control. These Gene
Circuits are designed to precisely kill cancer cells, spare healthy
cells, increase specificity to target cells and control the
expression of drugs even after administration. The Company’s
wholly-owned pipeline utilizes off-the-shelf CAR-NK cells,
outfitted with Gene Circuits, to target challenging liquid and
solid tumor indications. Senti Bio has also preclinically
demonstrated the potential breadth of Gene Circuits in other
modalities, diseases outside of oncology, and continues to advance
these capabilities through partnerships with Spark Therapeutics and
BlueRock Therapeutics.
Forward-Looking StatementsThis press release
and document contain certain statements that are not historical
facts and are considered forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally are identified by the
words “believe,” “could,” “predict,” “continue,” “ongoing,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
“forecast,” “seek,” “target” and similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. Forward-looking statements are predictions,
projections, and other statements about future events that are
based on current expectations of Senti Bio’s management and
assumptions, whether or not identified in this document, and, as a
result, are subject to risks and uncertainties. Forward-looking
statements include, but are not limited to, statements regarding
Senti Bio’s participation in upcoming conferences, expectations
regarding Senti Bio’s growth, strategy, progress and timing of its
clinical trials for SENTI-202; the timing of availability of data
from the ongoing Phase 1 clinical trial of SENTI-202; expectations
regarding the anticipated dosing of patients and availability of
data from clinical trials, and the timing thereof; the ability to
initiate new clinical programs as well as statements about the
potential attributes and benefits of Senti Bio’s platform
technology. These forward-looking statements are provided for
illustrative purposes only and are not intended to serve as and
must not be relied on by any investor as, a guarantee, an
assurance, a prediction, or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict and will differ from assumptions. Many actual
events and circumstances are beyond the control of Senti Bio. Many
factors could cause actual future results to differ materially from
the forward-looking statements in this document, including but not
limited to: (i) changes in domestic and foreign business, market,
financial, political and legal conditions, (ii) changes in the
competitive and highly regulated industries in which Senti Bio
operates, variations in operating performance across competitors,
changes in laws and regulations affecting Senti Bio’s business,
(iii) the ability to implement business plans, forecasts and other
expectations, (iv) the risk of downturns and a changing regulatory
landscape in Senti Bio’s highly competitive industry, (v) risks
relating to the uncertainty of any projected financial information
with respect to Senti Bio, (vi) risks related to uncertainty in the
timing or results of Senti Bio’s clinical trial start up, clinical
studies, patient enrollment, and GMP manufacturing startup
activities, (vii) Senti Bio’s dependence on third parties in
connection with clinical trial startup, clinical studies, and GMP
manufacturing activities, (viii) risks related to delays and other
impacts from macroeconomic and geopolitical events, increasing
rates of inflation and rising interest rates on business
operations, (ix) risks related to the timing and utilization of the
grant from CIRM, and (x) the success of any future research and
development efforts by Senti Bio. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the “Risk
Factors” section of Senti Bio’s Quarterly Report on Form 10-Q,
filed with the U.S. Securities and Exchange Commission (“SEC”) on
August 13, 2024, and other documents filed by Senti Bio from time
to time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements in this document. There may be
additional risks that Senti Bio does not presently know, or that
Senti Bio currently believes are immaterial that could also cause
actual results to differ from those contained in the
forward-looking statements in this document. Forward-looking
statements speak only as of the date they are made. Senti Bio
anticipates that subsequent events and developments may cause Senti
Bio’s assessments to change. Except as required by law, Senti Bio
assumes no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
Availability of Other Information About Senti
Biosciences, Inc.For more information, please visit the
Senti Bio website at https://www.sentibio.com or follow Senti Bio
on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti
Biosciences). Investors and others should note that we communicate
with our investors and the public using our company website
(www.sentibio.com), including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on X and LinkedIn.
The information that we post on our website or on X or LinkedIn
could be deemed to be material information. As a result, we
encourage investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website or social media shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Senti Bio ContactsInvestors:
investors@sentibio.comMedia: media@sentibio.com
Senti Biosciences (NASDAQ:SNTI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Senti Biosciences (NASDAQ:SNTI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024